Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 106

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 106
---
of Series B Preferred shall be entitled to receive, prior and in preference to any distribution of any of the assets or surplus funds
of the Company to the holders of common stock, an amount per share in cash equal to the greater of (x) the stated value of $6.50 for each
share of Series B Preferred then held by the holder or (y) the amount payable per share of common stock which such holder of Series B
Preferred would have received if such Holder had converted to common stock immediately prior to the Liquidation Event.

Share-Based Compensation

2020 Omnibus Incentive Plan

On October 21, 2020, we adopted our 2020 Omnibus Incentive
Plan (the “2020 Plan”) and on October 22, 2020, the 2020 Plan was approved by our stockholders. The 2020 Plan was adopted
to promote our long-term success and the creation of stockholder value by motivating participants, through equity incentive awards, to
achieve long-term success in our business. The 2020 Plan permits the discretionary award of stock options, restricted stock, RSUs, and
other equity awards to selected participants. On October 21, 2021, the first anniversary date from the adoption date of the 2020 Plan,
the number of shares of common stock reserved for issuance under the 2020 Plan increased to 20% of the fully diluted shares of common
stock outstanding, including shares of common stock reserved for issuance under convertible securities. As of December 31, 2024, we have
reserved 1,661,966 shares of common stock for issuance under the 2020 Plan, of which 510,513 were subject to outstanding RSUs and 1,137,409
shares were available for future grants of share-based awards.

     F-19 

    Mosaic ImmunoEngineering, Inc.

    Notes to Consolidated Financial Statements
    For the Years Ended December 31, 2024 and 2023 (continued)

The cost of all share-based awards will be recognized
in the consolidated financial statements based on the fair value of the awards. The fair value of stock option awards will be determined
using the Black-Scholes valuation model on the date of grant. The fair value of restricted stock awards and RSUs will be equal to the
closing market price of our common stock on the date of grant. The Company will generally recognize share-based compensation expense over
the period of vest